Frühe Implementierung der „Fantastic four“ bei Herzinsuffizienz mit reduzierter Ejektionsfraktion

Die aktuelle ESC-Leitlinie beinhaltet nicht nur neue medikamentöse Behandlungsmöglichkeiten, sondern auch die Etablierung der Therapie selbst. So wird eine möglichst frühzeitige Behandlung mit 4 die Prognose verbessernden Wirkstoffklassen bei Herzinsuffizienz-Patienten mit reduzierter Ejektionsfraktion empfohlen. Folgende Übersicht gibt einen praktischen Leitfaden zum sicheren und patientenorientierten Einsatz der Herzinsuffizienz-Medikation.

Abstract

The 2021 guidelines of the European Society of Cardiology for the diagnosis and treatment of heart failure recommend the early implementation of all four mortality-lowering drug classes for heart failure with reduced ejection fraction (HFrEF), i. e. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor II blocker-neprilysin inhibitor (ARNI), betablocker (BB), mineralocorticoid receptor-antagonists (MRA), and sodium-glucose linked transporter-2 inhibitors (SGLT2i). This article aims to give a practical compendium supporting physicians to enable safe and efficacious treatment for patients with HFrEF.

Schlüsselwörter

Herzinsuffizienz - leitliniengerechte medikamentöse Therapie - HFrEF

Key words

heart failure - guideline-compliant drug therapy - HFrEF

Publication History

Article published online:
22 July 2022

• Literatur

• 1 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726 DOI: 10.1093/eurheartj/ehab368.
• 2 Investigators*. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. New Engl J Medicine 1991; 325: 293-302 DOI: 10.1056/nejm199108013250501.
• 3 Wollert KC, Drexler H. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation 2002; 106: 2164-2166 DOI: 10.1161/01.cir.0000038702.35084.d6.
• 4 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New Engl J Med 2019; 381: 1995-2008 DOI: 10.1056/nejmoa1911303.
• 5 McMurray JJV, Packer M, Desai AS. et al. Angiotensin – Neprilysin Inhibition versus Enalapril in Heart Failure. New Engl J Med 2014; 371: 993-1004 DOI: 10.1056/nejmoa1409077.
• 6 Pitt B, Remme W, Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321 DOI: 10.1056/NEJMoa030207.
• 7 Packer M, Anker SD, Butler J. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383 (15) 1413-1424
• 8 Abdin A, Bauersachs J, Frey N. et al. Timely and individualized heart failure management: need for implementation into the new guidelines. Clin Res Cardiol 2021; 110: 1150-1158 DOI: 10.1007/s00392-021-01867-2.
• 9 Rosano GMC, Allen LA, Abdin A. et al. Drug Layering in Heart Failure: Phenotype-Guided Initiation. JACCHeart failure 2021; 9: 775-783 DOI: 10.1016/j.jchf.2021.06.011.
• 10 McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. Circulation 2021; 143: 875-877 DOI: 10.1161/CIRCULATIONAHA.120.052926.
• 11 Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J 2021; 42: 681-683 DOI: 10.1093/eurheartj/ehaa1012.
• 12 Velazquez EJ, Morrow DA, DeVore AD. et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. New Engl J Med 2019; 380: 539-548 DOI: 10.1056/NEJMoa1812851.
• 13 Vaduganathan M, Claggett BL, Jhund PS. et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England) 2020; 396: 121-128 DOI: 10.1016/S0140-6736(20)30748-0.
• 14 Butler J, Anstrom KJ, Felker GM. et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA cardiology 2017; 2: 950-958 DOI: 10.1001/jamacardio.2017.2198.
• 15 Pardo-Martínez P, Barge-Caballero E, Bouzas-Mosquera A. et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur J Intern Med 2022; 97: 86-94 DOI: 10.1016/j.ejim.2021.12.027.
• 16 Voors AA, Angermann CE, Teerlink JR. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022; 1-7 DOI: 10.1038/s41591-021-01659-1.
• 17 Bozkurt B, Coats AJS, Tsutsui H. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail 2021; 23: 352-380 DOI: 10.1002/ejhf.2115.
• 18 Halliday BP, Wassall R, Lota AS. et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet Lond Engl 2019; 393: 61-73 DOI: 10.1016/s0140-6736(18)32484-x.
• 19 Marti CN, Fonarow GC, Anker SD. et al. Medication dosing for heart failure with reduced ejection fraction – opportunities and challenges. Eur J Heart Fail 2019; 21: 286-296 DOI: 10.1002/ejhf.1351.
• 20 Swedberg K, Komajda M, Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885 DOI: 10.1016/s0140-6736(10)61198-1.
• 21 Armstrong PW, Pieske B, Anstrom KJ. et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New Engl J Med 2020; 382: 1883-1893 DOI: 10.1056/NEJMoa1915928.